Evidence map›Paper›PMID 42025328›Full record

ReviewEuropean heart journal. Cardiovascular Imaging2026

Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC.

Giuseppina Novo, Teresa Lopez-Fernandez, Victoria Delgado, Patrizio Lancellotti, Ana G Almeida, Jutta Bergler-Klein, Jelena Celutkiene, Marc R Dweck, Marco Guglielmo, Geeta Gulati and 4 more

Abstract readConsensus StatementReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Giuseppina NovoDepartment of Health Promotion, Maternal and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.ORCID 0000-0003-2127-7351
Teresa Lopez-FernandezCardiology Department, Cardio-Oncology Unit, La Paz University Hospital, Idi PAZ Research Institute, Madrid, Spain.
Victoria DelgadoHeart Institute Hospital University Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0002-9841-2737
Patrizio LancellottiCardiovascular & Metabolism, Department of Cardiology, University of Liège Hospital, GIGA Institutes, CHU Sart Tilman, Liège, Belgium.
Ana G AlmeidaFaculty of Medicine of Lisbon University, Cardiology, Heart and Vessels Department, CCUL@RISE, ULS Santa Maria, Lisbon, Portugal.
Jutta Bergler-KleinDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2591-1380
Jelena CelutkieneDepartment of Cardiac and Vascular Diseases, Faculty of Medicine, Centre of Innovative Medicine, Vilnius University, Vilnius, Lithuania.
Marc R DweckBHF Centre for Cardiovascular Sciences, University of Edinburgh, Little France Crescent, Little France, Edinburgh, UK.
Marco GuglielmoDivision of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Geeta GulatiDivision of Medicine, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway.ORCID 0000-0002-1316-8676
Saeed MirsadraeeDepartment of Radiology, Royal Brompton Hospital, London, UK.
Muhammad Sohaib NazirSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Alexander R LyonCardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.
Ivan StankovicDepartment of Cardiology, Faculty of Medicine, Clinical Hospital Centre Zemin, University of Belgrade, Belgrade, Serbia.ORCID 0000-0001-5825-5821

Funding

Foundation Leducq Network of Excellence in Cardio-OncologyHeart Foundation
6 · The paper itself

Abstract

Early detection of cancer and advances in treatment have significantly improved the survival rate of patients with cancer. Both cancer and its treatment can accelerate the onset of cardiovascular disease, adversely affecting prognosis of patients with cancer and survivors. Coronary artery disease (CAD) and peripheral artery disease (PAD) are common complications in patients with cancer. Cardiovascular imaging plays a central role in baseline risk assessment, detection, and treatment planning. The indications for the use of various imaging modalities are similar as in the general population. However, due to unique pathophysiological characteristics and clinical presentations of this population, the use of cardiac imaging in these vulnerable patients often needs to be adapted to the clinical circumstances and individual patient characteristics. In this clinical consensus statement, the European Society of Cardiology (ESC) Council of Cardio-Oncology and the European Association of Cardiovascular Imaging of the ESC have reviewed and summarized the current evidence in this field to aid clinicians in the selection of appropriate imaging modalities for the diagnosis, monitoring, and treatment of CAD and PAD in patients with cancer.

Indexed as

Antineoplastic AgentsCoronary Artery DiseaseMultimodal ImagingNeoplasmsPeripheral Arterial DiseaseCardio-OncologyCardiotoxicityEuropeFemaleHumansMaleRisk AssessmentAntineoplastic Agentscardiac magnetic resonancecardio-oncologycardiotoxicitycomputed tomographycoronary artery diseaseechocardiographyperipheral artery disease

Identifiers

PMID42025328
PMCPMC13314027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.